Glympse Bio

Glympse Bio is now merged with Sunbird Bio!

[Glympse Bio @GlympseBio]

#NEWS: Glympse Bio is now merged with Sunbird Bio! Read the press release: https://t.co/XKDx5KcY8C

[Glympse Bio @GlympseBio]

Speaking with @karenjagoda of the Empowered Patient Podcast, CMO Dr. Tram Tran discusses how Glympse’s #diagnostic platform simplifies things in the clinic and for the patient using a simple blood-based test.

Listen to the podcast here: https://t.co/bcfmRo9AnG

[Glympse Bio @GlympseBio]

On behalf of the entire team at Glympse, we hope you have a very happy Thanksgiving!

[Glympse Bio @GlympseBio]

Glympse is developing #technology that can non-invasively measure protein activity to #diagnose and monitor disease.

Learn more by viewing the animation on our website: https://t.co/6kG0wU61ZC

[Glympse Bio @GlympseBio]

Watch: Dr. Amit Singal (@docamitgs) of @utswcancer discusses the need for early #HCC diagnosis and the #TLM22 data demonstrating that Glympse's biosensor platform can sensitively detect HCC.

https://t.co/abrY3EsBPk

[Glympse Bio @GlympseBio]

#TLM22 begins today!

Glympse and Dr. Amit Singal (@docamitgs) will present a poster on Monday 11/7 from 1-2 PM that demonstrates our biosensors can sensitively detect HCC. We hope to see you then!

You can view the poster on our website: https://t.co/heer0q3Pls

@AASLDtweets

[Glympse Bio @GlympseBio]

Glympse will present a poster at @AASLDtweets #TLM22 demonstrating the sensitive detection of #HCC by our novel diagnostic platform.
You can see the poster on Monday, Nov. 7 from 1-2 PM and find more information in our announcement: https://t.co/fYMiGN624d

[Glympse Bio @GlympseBio]

A recent @HealioGastro article highlights how #NASH is the fastest growing cause of hepatocellular carcinoma (#HCC) in the US and of #livercancer deaths worldwide.

Glympse’s platform and diagnostic potential seeks to help reverse this trend.

https://t.co/hQkzkywOcc

[Glympse Bio @GlympseBio]

Glympse celebrated the #autumn season with an #applepicking event! We had a wonderful day spending this quality time together as a team. #teamwork

[Glympse Bio @GlympseBio]

October is #LiverAwarenessMonth. Liver disease takes many forms and can significantly impact a patient's quality of life. Glympse is dedicated to developing diagnostics to help improve treatments for patients with #liverdisease.
Learn more from @liverUSA: https://t.co/csV2T7u6tV

[Glympse Bio @GlympseBio]

#ICYMI, our #CMO Tram Tran, MD, wrote an article for @Tech_Networks about the burden of #liverdisease on the healthcare system and the role #diagnostics like Glympse’s can play in alleviating this.

Read Tram’s article here: https://t.co/IqCTPBusBy

[Glympse Bio @GlympseBio]

Shout out to our new #CSO, Dr. Jonathan Wilde! Since joining the team earlier this year, Dr. Wilde’s scientific expertise has been integral in the development of our novel protein activity biosensor #diagnostic platform.

[Glympse Bio @GlympseBio]

On this week’s episode of @PharmaVoice’s #WomanOfTheWeek podcast, CMO Dr. Tram Tran shares the inspirations that led to her career path in #medicine and work on Glympse’s revolutionary diagnostic technology.

Listen to the full episode here: https://t.co/pYvmCQF2IV

[Glympse Bio @GlympseBio]

CMO Dr. Tram Tran sat down with @MyDocWire to discuss Glympse’s focus on early disease detection for #NASH and improving patient outcomes with its unique protein activity-based diagnostic platform.

Watch: https://t.co/lreInCMgyv

[Glympse Bio @GlympseBio]

#TeamGlympse wishes you a safe and happy #IndependenceDay!

[Glympse Bio @GlympseBio]

Tomorrow, June 24, Dr. Amit Singal (@docamitgs) will present findings at #ILC2022 demonstrating that #Glympse’s biosensor platform can detect #HCC from non-HCC patients with liver cirrhosis from a blood sample.

See the poster here: https://t.co/sGyiJvXZsI

[Glympse Bio @GlympseBio]

On Saturday, June 25, CMO Tram Tran, M.D. will present a poster at @EASLNews’s #ILC2022 demonstrating our novel protease biosensor diagnostic platform’s ability to distinguish NASH vs. healthy patients from a blood sample.

See the poster here: https://t.co/R2n5vo9vgg

[Glympse Bio @GlympseBio]

#Glympse CMO @TramTran_MD spoke with @AnnetteMBoyle of @BioWorld about our @EASLnews #ILC2022 data demonstrating early detection of #HCC from a simple blood test and the importance of this for patients.

Read more: https://t.co/xyrtTSqBbH

[Glympse Bio @GlympseBio]

Today is International #NASHDay. NASH is a severe form of fatty #liverdisease that affects millions worldwide. At #Glympse, we are developing technologies to improve how we diagnose and monitor NASH, so we can #StopNASHNow.

Learn more from @globalliver: https://t.co/XW7jZyua9T

[Glympse Bio @GlympseBio]

#Glympse will present two posters on the accuracy of its protease biosensor diagnostic platform in detecting patients with hepatocellular carcinoma (#HCC) at the @EASLnews International Liver Congress 2022 #ILC2022.

Find out more: https://t.co/uF3d1Jxk7F